Trading Sections
Snap: 19% Revenue Increase and Rising Advertising Revenue as Indicators of Operational Turnaround - Barclays Raises Target to $16!
Fundamentals of the Business Model Snap Inc. (SNAP) operates as a technology and social media company....
D-Wave Quantum: Partnership with Nasdaq Verafin - Wedbush Sees 100% Upside Potential for the Stock!
D-Wave Quantum (QBTS) follows a dual-platform approach in quantum computing. A new partnership with...
Nextpower: Acquisitions Reinforce Expansion Strategy - KeyBanc Issues Buy Recommendation with 66% Upside Potential!
Nextpower (NXT) (i.) (formerly known as Nextracker) is a global leader in technology within the renewable...
Coreweave: Government Contract with Leidos and Capacity Expansion in Focus – Analysts Assess Meta Risk
CoreWeave (CRWV) announced a strategic partnership with Leidos on July 30 to build a specialized and...
Medios: Record Revenue Meets Margin Pressure – Berenberg Sees 124% Price Potential
Medios AG (i.) raises its forecast for total revenues after a strong first half of the year, but lowers...
Q32 Bio: Positive Phase-2 Data on Bempikibart - H.C. Wainwright Sees 134% Price Potential!
The biotech company Q32 Bio (QTTB) released encouraging 36-week results from the Phase 2a study of Bempikibart...
Aduro Clean Technologies: Fresh Capital, Strategic Partnerships, and Tailwind from Roth Capital
The market environment for companies in the field of chemical recycling of waste materials is developing...
Nokia: AI Order Wave and Growing Infrastructure Business Shape Q2 - BofA Sees 87% Upside Potential
Nokia: AI Order Wave and Growing Infrastructure Business Shape Q2 - BofA Sees 87% Upside Potential ...
IREN Ltd.: Billion-Dollar Contracts and Analyst Upgrades Support the Transition to an AI Infrastructure Provider
New AI cloud contracts worth $2.8 billion with developers like Microsoft, NVIDIA, and Perplexity drive...
Trevi Therapeutics: Analysts See Great Opportunities for Haduvio After GSK Setback
Clear Street increases the target price for Trevi Therapeutics to $40 after rival GSK halts the development...
Gloo Holdings: Insider Purchases in Millions and an Optimistic Analyst Rating Support the Stock
Gloo Holdings Inc. (GLOO) has recently gained attention due to massive insider purchases amounting to...
Array Technologies: Strategic Acquisition of AWM and Diverging Analyst Opinions
Array Technologies (ARRY) acquires Affordable Wire Management (AWM) for up to 203 million USD. With this...
Annexon Biosciences: Tailwind from Analysts – Pipeline Progress and Price Potential in Focus
In July, the analysis firms Wells Fargo and Needham reaffirmed their buy recommendations for Annexon...
Lyft: AI Focus through New CTO and Spain Expansion Meets 89% Price Potential
On July 7, 2026, Lyft announced the appointment of Senthil Padmanabhan, a former eBay manager, as the...
Critical Metals: Focus on the Greenland Tanbreez Project and Ambitious Analyst Target Driving the Stock
Cantor Fitzgerald initiated coverage of Critical Metals (CRML) on July 14 with a "Speculative Buy" rating...
Candel Therapeutics: Compelling Clinical Phase 3 Data and a $22 Price Target by Stifel!
Candel Therapeutics (CADL) recently published crucial Phase 3 data (PrTK03) for its lead candidate Aglatimagene...
Alpha Cognition: Zunveyl growth and new studies strengthen its profile in the Alzheimer's market
Raymond James initiated coverage of the stock of Alpha Cognition (ACOG) on July 10, 2026, with an "Outperform"...
BioAge Labs: How Novo Nordisk's ZEUS Study Could Validate the Market for the NLRP3 Inhibitor BGE-102
In mid-June 2026, BioAge Labs (BIOA) dosed the first patient in the QUELL-CV study to test the oral...
FDA Approval and Accelerated Efficacy Data: How Vera Therapeutics Addresses the Multi-Billion Dollar Kidney Disease Market with Trutakna
Classification of the FDA Decision and Market Dynamics On July 7, 2026, the California-based biotech...
AtaiBeckley: Canaccord Raises Target to $17 and Praises Progress in DMT Buccal Film Study!
The biopharma sector continues to experience steady interest in companies dedicated to developing novel...
Arcturus Therapeutics: Strategic Focus on Rare Diseases and Thermo Fisher Alliance Bring mRNA Specialists into Analyst Spotlight
Arcturus secures industry giant Thermo Fisher Scientific as a strategic partner for the phase 3 development...
Nemetschek: AI initiatives and M&A strategy underpin analyst price target of 110 euros
US bank JPMorgan maintains the Nemetschek stock rating at "Overweight" after a recent management discussion,...
Larimar Therapeutics aims to file BLA for Nomlabofusp: H.C. Wainwright expects market launch in 2027 and billion-dollar revenue
H.C. Wainwright begins coverage of the Larimar stock with a "Buy" recommendation and a price target of...